Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants.
Mamedov T, Yuksel D, Gurbuzaslan I, Gulec B, Mammadova G, Ozdarendeli A, Pavel STI, Yetiskin H, Kaplan B, Uygut MA, Hasanova G. Mamedov T, et al. Among authors: ozdarendeli a. Front Plant Sci. 2023 Nov 14;14:1290042. doi: 10.3389/fpls.2023.1290042. eCollection 2023. Front Plant Sci. 2023. PMID: 38034565 Free PMC article.
A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™).
Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, Karakukçu M, Kırbaş OK, Gökdemir NS, Bozkurt BT, Özkul Y, Oktay BD, Uygut MA, Cinel I, Çetin M. Gül F, et al. Among authors: ozdarendeli a. Front Immunol. 2022 Nov 9;13:963309. doi: 10.3389/fimmu.2022.963309. eCollection 2022. Front Immunol. 2022. PMID: 36439138 Free PMC article.
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A, Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Bayram A, Mazicioglu M, Unuvar GK, Yuce ZT, Aydin G, Aslan AF, Kaya RK, Koc RC, Ates I, Kara A. Ozdarendeli A, et al. Vaccine. 2023 Jan 9;41(2):380-390. doi: 10.1016/j.vaccine.2022.10.093. Epub 2022 Nov 22. Vaccine. 2023. PMID: 36460536 Free PMC article.
Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.
Mamedov T, Yuksel D, Gurbuzaslan I, Ilgin M, Gulec B, Mammadova G, Ozdarendeli A, Pavel STI, Yetiskin H, Kaplan B, Uygut MA, Hasanova G. Mamedov T, et al. Among authors: ozdarendeli a. Front Plant Sci. 2023 Aug 2;14:1202570. doi: 10.3389/fpls.2023.1202570. eCollection 2023. Front Plant Sci. 2023. PMID: 37600182 Free PMC article.
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.
Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Aslan AF, Bayram A, Mazicioglu M, Kalin Unuvar G, Yuce ZT, Aydin G, Kaya RK, Ates I, Kara A, Ozdarendeli A. Sezer Z, et al. Among authors: ozdarendeli a. Vaccines (Basel). 2024 Jan 29;12(2):140. doi: 10.3390/vaccines12020140. Vaccines (Basel). 2024. PMID: 38400124 Free PMC article.
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study.
Ates I, Batirel A, Aydin M, Karadag FY, Erden A, Kucuksahin O, Armagan B, Guven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Omma A, Kara A. Ates I, et al. Among authors: ozdarendeli a. Vaccines (Basel). 2023 Jul 12;11(7):1234. doi: 10.3390/vaccines11071234. Vaccines (Basel). 2023. PMID: 37515050 Free PMC article.
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial.
Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, Kose S, Akhan S, Akalin EH, Sezer Z, Ozdarendeli A, Unal S, On Behalf Of The Turkovac Study Group. Tanriover MD, et al. Among authors: ozdarendeli a. Vaccines (Basel). 2022 Nov 4;10(11):1865. doi: 10.3390/vaccines10111865. Vaccines (Basel). 2022. PMID: 36366373 Free PMC article.
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Güven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Kara A, Ates I. Omma A, et al. Among authors: ozdarendeli a. Hum Vaccin Immunother. 2022 Nov 30;18(6):2122503. doi: 10.1080/21645515.2022.2122503. Epub 2022 Oct 31. Hum Vaccin Immunother. 2022. PMID: 36315843 Free PMC article. Clinical Trial.
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.
Taşlı NP, Gönen ZB, Kırbaş OK, Gökdemir NS, Bozkurt BT, Bayrakcı B, Sağraç D, Taşkan E, Demir S, Ekimci Gürcan N, Bayındır Bilgiç M, Bayrak ÖF, Yetişkin H, Kaplan B, Pavel STI, Dinç G, Serhatlı M, Çakırca G, Eken A, Aslan V, Yay M, Karakukcu M, Unal E, Gül F, Basaran KE, Ozkul Y, Şahin F, Jones OY, Tekin Ş, Özdarendeli A, Cetin M. Taşlı NP, et al. Among authors: ozdarendeli a. Front Immunol. 2022 Mar 24;13:824378. doi: 10.3389/fimmu.2022.824378. eCollection 2022. Front Immunol. 2022. PMID: 35401544 Free PMC article.
48 results